Summary: In October of 2010, the U.S. Food and Drug Administration approved a new oral direct thrombin inhibitor for prevention of stroke and thrombosis in patients with atrial fibrillation. This marked a new era in the development of fixed dose novel oral anticoagulants, with a hope of achieving improved safety and clinical outcomes compared to warfarin.
